Allogene Therapeutics (ALLO) vs Entera Bio (ENTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Allogene Therapeutics is the larger company by market cap ($494.1 million vs $436.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | ALLO | ENTX |
|---|---|---|
| Share price | $1.43 | $2.51 |
| Market cap | $494.05M | $436.32M |
| 1-day change | -2.05% | -0.79% |
| YTD return | — | +29.38% |
| 1-year return | — | +32.80% |
| 5-year return | — | -44.47% |
| EPS (TTM) | $-0.66 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.46 | $4.20 |
| 52-week low | $1.04 | $0.91 |
| Distance from 52-week high | -67.94% | -40.24% |
| Average volume | 5.78M | 1.81M |
| Shares outstanding | 345.49M | 173.83M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
ALLO vs ENTX FAQ
Which is bigger, Allogene Therapeutics or Entera Bio?
Allogene Therapeutics (ALLO) is larger, with a market capitalization of $494.05M compared with $436.32M for Entera Bio (ENTX).
Are Allogene Therapeutics and Entera Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.